Patent · US Active

Bispecific antigen binding molecules comprising anti-FAP clone 212

US11242396B2 · kind B2 · utility

9Cited by

9References

36Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Peter Bruenker · Hittnau, CH
Harald Duerr · Starnberg, DE
Christian Klein · Iffeldorf, DE
Pablo Umana · Wollerau, CH
Alexander BUJOTZEK · Penzberg, DE
Joerg ZIELONKA · Schlieren, CH
Christine TRUMPFHELLER · Schlieren, CH
Moritz RAPP · Schlieren, CH
Marine LE CLECH · Schlieren, CH

Key dates

Filing date	Sep 30, 2019
Grant date	Feb 8, 2022
Priority date	—
Expiry date	Sep 30, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.